TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Oncotarget · 2016 · PMC5078047 · PMID 27129168

Europe PMC DOI

hedged sentence

0.0920

closest p · 1.8× alpha

0.0920

boldest claim

The sentences

showed a trendp = 0.092so close (0.05 < p ≤ 0.1)

By contrast, HER2-positive patients with TP53 mutant tumors showed a trend for longer DFS than those without (HR = 0.69; 95% CI 0.45 – 1.06; p = 0.092).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.